Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus cabozantinib versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma
2017-000759-20Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Nivolumab plus cabozantinib with Sunitinib (2 arms). Primary endpoint: Progression-free survival. Started May 2017; status: active.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2017-000759-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000759-20.